Corporate mission
Hubro Bioscience is founded on its frameshift mutation targeting technology platform. The overarching goal of the company is to develop novel diagnostic tests for early detection of cancer biomarkers in liquid biopsies. Through the further development of the capacities of its technology, the company seeks to develop strong product candidates and explore these opportunities alone and/or in partnership with other companies and institutions.
There is a wide scope of strategic and operational possibilities for the company, and it will tirelessly explore the most interesting paths, and create results which will provide better cancer care to improve the prognosis and the quality of the lives of at-risk individuals and families.
